Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-06-14
2009-10-27
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07608586
ABSTRACT:
A soluble derivative of low-density lipoprotein receptor related protein-1 (sLRP-1) binds directly to Alzheimer's amyloid-β peptide (Aβ). This binding may be used to detect Aβ or to separate Aβ from the rest of a subject's body. In Alzheimer's disease, it may be used to provide diagnostic results by detecting Aβ, treatment by removing Aβ, or both.
REFERENCES:
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4900747 (1990-02-01), Vlassara et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5208154 (1993-05-01), Weaver et al.
patent: 5221628 (1993-06-01), Anderson et al.
patent: 5316754 (1994-05-01), Vlassara et al.
patent: 5766856 (1998-06-01), Imani et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5932580 (1999-08-01), Levitzki et al.
patent: 5962245 (1999-10-01), Li et al.
patent: 6156311 (2000-12-01), Strickland et al.
patent: 6242416 (2001-06-01), Gilchrest et al.
patent: 6410598 (2002-06-01), Vitek et al.
patent: 6413512 (2002-07-01), Houston et al.
patent: 6428967 (2002-08-01), Herz et al.
patent: 6447775 (2002-09-01), Strickland et al.
patent: 6472140 (2002-10-01), Tanzi et al.
patent: 6677299 (2004-01-01), Stern et al.
patent: 6825164 (2004-11-01), Stern et al.
patent: 7056688 (2006-06-01), Herz et al.
patent: 7192714 (2007-03-01), Herz et al.
patent: 2002/0172676 (2002-11-01), Jackowski et al.
patent: 2004/0038338 (2004-02-01), Koo et al.
patent: 2004/0259159 (2004-12-01), Zlokovic
patent: 2005/0227941 (2005-10-01), Duff et al.
patent: 2005/0239062 (2005-10-01), Zlokovic
patent: 2006/0034848 (2006-02-01), Kinoshita et al.
patent: 2006/0088528 (2006-04-01), Hyman et al.
patent: 2007/0253950 (2007-11-01), Jacobsen
patent: WO 97/04794 (1997-02-01), None
patent: WO 01/90758 (2001-11-01), None
patent: WO 02/14519 (2002-02-01), None
patent: WO 2005/122712 (2005-12-01), None
patent: 2007/059242 (2007-05-01), None
patent: 2007/089616 (2007-08-01), None
Neels et al. 1999. Journal of Biological Chemistry 274:31305-31311.
Lo et al. 1998. Protein Engineering 11:495-500.
Bell et al. “Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system” J. Cereb. Blood Flow & Metab. 27:909-918 (May 2007) but the submitted copy is the earlier available epublication on Nov. 1, 2006.
Bu et al. “39 kDA receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein” EMBO J. 14:2269-2280 (1995).
Bu et al. “Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein” J. Biol. Chem. 271:2218-2224 (1996).
Cam et al. “Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the β-amyloid precursor protein” J. Biol. Chem. 280:15464-15470 (Apr. 2005).
Deane et al. “LRP/amyloid β-peptide interactionmediates differential brain efflux of Aβ isoforms” Neuron 43:333-344 (Aug. 2004).
Deane et al. “IgG-Assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor” J. Neurosci. 25:11495-11503 (Dec. 2005).
Horn et al. “Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein” J. Biol. Chem. 272:13608-13613 (1997).
Moestrup et al. “α2-Macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the α2-macroglobulin receptor containing a cluster of eight complement-type repeats” J. Biol. Chem. 268:13691-13696 (1993).
Sagare et al. “Clearance of amyloid-β by circulating lipoprotein receptors” Nature Med. doi:10.1038
m1635, 21 pages, the submitted copy is the earlier available epublication on Aug. 12, 2007.
Willnow et al. “Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein” J. Biol. Chem. 269:15827-15832 (1994).
Deane et al. “RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain” Nature Medicine 9:907-913 (2003).
DeMattos et al. “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease” Proc. Natl. Acad. Sci. USA 98:8850-8855 (2001).
Ghersi-Egea et al. “Fate of cerebrospinal fluid-borne amyloid β-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries” J. Neurochem. 67:880-883 (1996).
Ghilardi et al. “Intra-arterial infusion of [125I]Aβ1-40 labels amyloid deposits in the aged primate brain in vivo” NeuroReport 7:2607-2611 (1996).
Jordan et al. “Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures” J. Neurosci. 18:195-204 (1998).
Iwata et al. “Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical pathological deposition” Nature Medicine 6:143-150 (2000).
Lucarelli et al. “Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels” FEBS Letters 401:53-58 (1997).
Mackic et al. “Human blood-brain barrier receptors for Alzheimer's amyloid-β 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer” J. Clin. Invest. 102:734-743 (1998).
Mackic et al. “Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid aniopathy” J. Neurochem. 70:210-215 (1998).
Maness et al. “Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier” Life Sciences 55:1643-1650 (1994).
Martel et al. “Isoform-specific effects of apolipoprioteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β” J. Neurochem. 69:1995-2004 (1997).
Mattson et al. “Amyloid ox-tox transducers” Nature 382:674-675 (1996).
Narita et al. “α2-macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein” J. Neurochem. 69:1904-1911 (1997).
Poduslo et al. “Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier” Neurobiol. Dis. 4:27-34 (1997).
Qiu et al. “α2-macroglobulin enhances the clearance of endogenous soluble β-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons” J. Neurochem. 73:1393-1398 (1999).
Schmidt et al. “Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins” Proc. Natl. Acad. Sci. USA 91:8807-8811 (1994).
Shibata et al. “Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier” J. Clin. Invest. 106:1489-1499, 2000.
Yan et al. “RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease” Nature 382:685-691 (1996).
Yan et al. “Receptor-dependent cells stress and amyloid accumulation in systemic amyloidosis” Nature Medicine 6:643-651 (2000).
Zlokovic “Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology” Neurobiol. Dis. 4:23-26 (1997).
Zlokovic et al. “Glycoprotein 330/megalin: Probable role in re
Deane Rashid
Zlokovic Berislav V.
Kolker Daniel E.
Nixon & Vanderhye P.C.
Socratech L.L.C.
The University of Rochester
LandOfFree
Soluble low-density lipoprotein receptor related protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble low-density lipoprotein receptor related protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble low-density lipoprotein receptor related protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097435